JONATHAN LEI to Protein Kinase Inhibitors
This is a "connection" page, showing publications JONATHAN LEI has written about Protein Kinase Inhibitors.
Connection Strength
0.318
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
Score: 0.169
-
Comprehensive evaluation of phosphoproteomic-based kinase activity inference. Nat Commun. 2025 May 22; 16(1):4771.
Score: 0.042
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.040
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
Score: 0.037
-
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020 11 25; 183(5):1436-1456.e31.
Score: 0.030